GD2-directed CAR-T therapies are advancing through neuroblastoma trials, adding a new modality to the anti-GD2 landscape. Specifically, third-generation GD2 CAR-T constructs have shown activity in relapsed or refractory high-risk neuroblastoma across recent phase 1/2 data. Consequently, the pipeline expands beyond monoclonal antibody therapy toward autologous cellular approaches for GD2-expressing disease.
DANYELZA remains the only humanized GD2-binding monoclonal antibody approved by the FDA for relapsed or refractory high-risk neuroblastoma. Furthermore, both antibody and CAR-T approaches target the same GD2 antigen but through fundamentally different mechanisms. Understanding the current on-label evidence base alongside the emerging pipeline supports informed conversations across pediatric oncology practice.
What Are Emerging GD2-Directed CAR-T Therapies in Neuroblastoma Trials?
Emerging GD2-directed CAR-T therapies in neuroblastoma trials are autologous cellular therapies engineered to target GD2 on tumor cells. Specifically, according to Locatelli (2025), third-generation GD2-CAR-T01 produced a 66 percent objective response rate in phase 1/2 evaluation. Consequently, cellular approaches to GD2 targeting are advancing alongside the established humanized monoclonal antibody DANYELZA.
The Current State of GD2-Directed CAR-T in Neuroblastoma Trials
GD2-directed CAR-T therapies are advancing through neuroblastoma trials as an emerging cellular immunotherapy approach. Specifically, according to Locatelli (2025), third-generation GD2-CART01 produced a 66 percent objective response rate in phase 1/2 evaluation. Consequently, cellular approaches to GD2 targeting are progressing alongside the established humanized monoclonal antibody DANYELZA.
The GD2-CART01 trial enrolled 54 children with high-risk metastatic, relapsed, or refractory neuroblastoma across the phase 1/2 evaluation. Furthermore, the third-generation construct incorporates an inducible caspase-9 suicide gene to enable rapid control of neurotoxicity. Grade 3 immune effector cell-associated neurotoxicity syndrome was documented in four patients across the trial.
Additional GD2-directed cellular approaches include CAR-NKT cells and first-generation constructs with extended follow-up periods. Additionally, Heczey (2023) reported updated interim results for anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma. Long-term outcomes from first-generation CAR-T constructs include documented responses extending beyond 18 years in individual cases.
The current state of GD2-directed CAR-T reflects an active investigational landscape rather than approved therapy at this point. Notably, all CAR-T approaches for neuroblastoma remain investigational under ongoing clinical trial evaluation. Ultimately, the pipeline represents a distinct treatment modality alongside approved anti-GD2 antibody therapy.
How CAR-T and Antibody Approaches Engage GD2 Differently
CAR-T and antibody approaches both target GD2 on neuroblastoma cells but engage the antigen through distinct mechanisms. Specifically, monoclonal antibody therapy delivers a preformed antibody that recruits host immune effector cells to GD2-expressing tumors. Consequently, engagement depends on host immune competence and effector cell availability at the site of disease.
CAR-T therapy involves autologous T cells genetically modified to express a chimeric antigen receptor targeting GD2 directly. Furthermore, the engineered T cells recognize and engage GD2-expressing tumor cells through the CAR construct rather than natural receptors. The approach expands the patient's own effector cell population against the target antigen at the tumor site.
Both approaches face the same underlying biology: GD2 is present on nerve tissue at lower levels alongside its overexpression on neuroblastoma cells. Additionally, safety profiles across both modalities reflect that shared antigen distribution across tumor and nerve tissue.
The mechanistic difference between antibody and CAR-T approaches shapes both safety and administration considerations across the two modalities. Ultimately, understanding the mechanisms informs clinical dialogue about anti-GD2 therapy across pediatric oncology practice.
DANYELZA's On-Label Evidence Base Under Accelerated Approval
DANYELZA's on-label evidence base rests on Study 12-230 and Study 201 across the accelerated approval framework. Specifically, both single-arm studies evaluated naxitamab plus GM-CSF in relapsed or refractory high-risk neuroblastoma in bone or bone marrow. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.
Study 12-230 evaluated 38 patients for efficacy and produced an overall response rate of 34 percent across the group. Furthermore, Study 201's initial analysis produced an ORR of 45 percent across 22 evaluable patients with a median DOR of 6.2 months. The pre-specified interim analysis of Study 201 produced an ORR of 40 percent across 52 evaluable patients.
The evidence base supports the current on-label indication and the accelerated approval pathway across the DANYELZA program. Additionally, responses documented in both studies were confirmed by revised INRC per Park (2017) across the evaluable populations.
Safety data across both studies reflect the boxed warning for serious infusion-related reactions and neurotoxicity. Ultimately, DANYELZA's on-label evidence base represents established antibody therapy alongside the investigational CAR-T pipeline.
The on-label indication and safety profile anchor current clinical use across US treating institutions. Consistent institutional documentation supports both individual patient care and the broader evidence base under accelerated approval.
What the Emerging Neuroblastoma Trials Landscape Means for Clinicians
The emerging neuroblastoma trials landscape means clinicians navigate an evolving field of GD2-directed approaches across the treatment course. Specifically, approved antibody therapy sits alongside investigational cellular approaches at different points in development. Consequently, clinicians should distinguish approved on-label options from investigational trial participation.
DANYELZA offers approved on-label therapy for relapsed or refractory high-risk neuroblastoma in bone or bone marrow with PR, MR, or SD. Furthermore, patients outside those criteria may be candidates for clinical trial participation across the investigational pipeline. Referral pathways to cooperative group trials support access to emerging approaches for eligible patients.
Communication with families about the emerging landscape requires clear framing of approved versus investigational options. Additionally, honest discussion of the current evidence base for each modality supports informed family decisions across the care pathway.
Ongoing clinical trial participation feeds the confirmatory evidence base across both approved and investigational therapies. Notably, documentation of on-label outcomes at treating institutions supports the DANYELZA confirmatory framework under accelerated approval.
The evolving neuroblastoma trials landscape reflects active pipeline development across GD2-directed approaches. Ultimately, clinicians play a role in both current patient care and future evidence generation across the field over time.
Partner With SERB to Support Your Anti-GD2 Immunotherapy Program
The GD2-directed treatment landscape spans approved antibody therapy and investigational cellular approaches across the pipeline. Specifically, DANYELZA anchors current on-label practice for relapsed or refractory bone or bone marrow disease with PR, MR, or SD. Continued approval may be contingent upon verification of clinical benefit in confirmatory trials.
Institutional readiness for anti-GD2 immunotherapy spans clinical understanding, patient selection, safety management, and family communication. Furthermore, informed conversations about the emerging pipeline support the broader clinical dialogue across the care team. Reach out to SERB for clinical resources that support your anti-GD2 immunotherapy program across your center.
Sources
- Locatelli F, Del Bufalo F, Quintarelli C, et al. GD2-targeting CAR T cells in high-risk neuroblastoma: a phase 1/2 trial. Nature Medicine. 2025.
- Heczey A, Xu X, Courtney AN, et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nature Medicine. 2023;29:1379-1388.
- Park JR, Bagatell R, Cohn SL, et al. Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting. Journal of Clinical Oncology. 2017;35(22):2580-2587.
